<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jiang J</submitter><funding>European Research Council</funding><funding>Biotechnology and Biological Sciences Research Council</funding><pagination>2782-false</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5654414</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(5)</volume><pubmed_abstract>GH29 α-l-fucosidases catalyze the hydrolysis of α-l-fucosidic linkages. Deficiency in human lysosomal α-l-fucosidase (FUCA1) leads to the recessively inherited disorder, fucosidosis. Herein we describe the development of fucopyranose-configured cyclophellitol aziridines as activity-based probes (ABPs) for selective &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i> labeling of GH29 α-l-fucosidases from bacteria, mice and man. Crystallographic analysis on bacterial α-l-fucosidase confirms that the ABPs act by covalent modification of the active site nucleophile. Competitive activity-based protein profiling identified l-fuconojirimycin as the single GH29 α-l-fucosidase inhibitor from eight configurational isomers.</pubmed_abstract><journal>Chemical science</journal><pubmed_title>&amp;lt;i&amp;gt;In vitro&amp;lt;/i&amp;gt; and &amp;lt;i&amp;gt;in vivo&amp;lt;/i&amp;gt; comparative and competitive activity-based protein profiling of GH29 α-l-fucosidases.</pubmed_title><pmcid>PMC5654414</pmcid><funding_grant_id>322942</funding_grant_id><funding_grant_id>1094267</funding_grant_id><pubmed_authors>van den Nieuwendijk AMCH</pubmed_authors><pubmed_authors>Jiang J</pubmed_authors><pubmed_authors>Donker-Koopman WE</pubmed_authors><pubmed_authors>Folch EC</pubmed_authors><pubmed_authors>Scheij S</pubmed_authors><pubmed_authors>Schurmann M</pubmed_authors><pubmed_authors>Verhoek M</pubmed_authors><pubmed_authors>Wright DW</pubmed_authors><pubmed_authors>van den Elst H</pubmed_authors><pubmed_authors>Davies GJ</pubmed_authors><pubmed_authors>Kallemeijn WW</pubmed_authors><pubmed_authors>Florea BI</pubmed_authors><pubmed_authors>Li N</pubmed_authors><pubmed_authors>van der Marel GA</pubmed_authors><pubmed_authors>Codee JDC</pubmed_authors><pubmed_authors>Overkleeft HS</pubmed_authors><pubmed_authors>Boot RG</pubmed_authors><pubmed_authors>Aerts JMFG</pubmed_authors><pubmed_authors>Rohde VC</pubmed_authors><pubmed_authors>Mink D</pubmed_authors></additional><is_claimable>false</is_claimable><name>&amp;lt;i&amp;gt;In vitro&amp;lt;/i&amp;gt; and &amp;lt;i&amp;gt;in vivo&amp;lt;/i&amp;gt; comparative and competitive activity-based protein profiling of GH29 α-l-fucosidases.</name><description>GH29 α-l-fucosidases catalyze the hydrolysis of α-l-fucosidic linkages. Deficiency in human lysosomal α-l-fucosidase (FUCA1) leads to the recessively inherited disorder, fucosidosis. Herein we describe the development of fucopyranose-configured cyclophellitol aziridines as activity-based probes (ABPs) for selective &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i> labeling of GH29 α-l-fucosidases from bacteria, mice and man. Crystallographic analysis on bacterial α-l-fucosidase confirms that the ABPs act by covalent modification of the active site nucleophile. Competitive activity-based protein profiling identified l-fuconojirimycin as the single GH29 α-l-fucosidase inhibitor from eight configurational isomers.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 May</publication><modification>2026-04-30T09:19:19.083Z</modification><creation>2019-03-26T23:02:45Z</creation></dates><accession>S-EPMC5654414</accession><cross_references><pubmed>29142681</pubmed><doi>10.1039/c4sc03739a</doi></cross_references></HashMap>